Immunovant

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immunovant and other ETFs, options, and stocks.

About IMVT

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor.

CEO

Eric Venker

CEOEric Venker

Employees

362

Employees362

Headquarters

New York, New York

HeadquartersNew York, New York

Founded

2018

Founded2018

Employees

362

Employees362

IMVT Key Statistics

Market cap

3.07B

Market cap3.07B

Price-Earnings ratio

-6.39

Price-Earnings ratio-6.39

Dividend yield

—

Dividend yield—

Average volume

1.19M

Average volume1.19M

High today

$19.06

High today$19.06

Low today

$17.39

Low today$17.39

Open price

$18.76

Open price$18.76

Volume

1.83M

Volume1.83M

52 Week high

$34.47

52 Week high$34.47

52 Week low

$12.72

52 Week low$12.72

Analyst ratings

79%

of 14 ratings

Buy

78.6%

Hold

21.4%

Sell

People also own

Based on the portfolios of people who own IMVT. This list is generated using Robinhood data, and it’s not a recommendation.